FR19C1071I2 - Inhibiteurs de type dihydropyridophthalazinone de poly(adp-ribose)polymerase (parp) - Google Patents
Inhibiteurs de type dihydropyridophthalazinone de poly(adp-ribose)polymerase (parp)Info
- Publication number
- FR19C1071I2 FR19C1071I2 FR19C1071C FR19C1071C FR19C1071I2 FR 19C1071 I2 FR19C1071 I2 FR 19C1071I2 FR 19C1071 C FR19C1071 C FR 19C1071C FR 19C1071 C FR19C1071 C FR 19C1071C FR 19C1071 I2 FR19C1071 I2 FR 19C1071I2
- Authority
- FR
- France
- Prior art keywords
- dihydropyridophthalazinone
- parp
- adp
- ribose
- polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8668708P | 2008-08-06 | 2008-08-06 | |
US15103609P | 2009-02-09 | 2009-02-09 | |
US17308809P | 2009-04-27 | 2009-04-27 | |
EP09805360.6A EP2326650B9 (de) | 2008-08-06 | 2009-07-27 | Dihydropyridophthalazinonhemmer der poly(adp-ribose)polymerase (parp) |
Publications (2)
Publication Number | Publication Date |
---|---|
FR19C1071I1 FR19C1071I1 (de) | 2020-01-17 |
FR19C1071I2 true FR19C1071I2 (fr) | 2020-10-16 |
Family
ID=41129519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR19C1071C Active FR19C1071I2 (fr) | 2008-08-06 | 2019-12-03 | Inhibiteurs de type dihydropyridophthalazinone de poly(adp-ribose)polymerase (parp) |
Country Status (31)
Country | Link |
---|---|
US (7) | US8012976B2 (de) |
EP (3) | EP2767537B1 (de) |
JP (3) | JP5984389B2 (de) |
KR (1) | KR101846029B1 (de) |
CN (3) | CN102171214B (de) |
AR (1) | AR072970A1 (de) |
AU (1) | AU2009279944B2 (de) |
BR (1) | BRPI0917119B1 (de) |
CA (1) | CA2732797C (de) |
CY (3) | CY1115022T1 (de) |
DK (2) | DK2326650T3 (de) |
ES (2) | ES2466565T3 (de) |
FR (1) | FR19C1071I2 (de) |
GB (1) | GB2462361A (de) |
HK (2) | HK1157755A1 (de) |
HR (1) | HRP20170982T1 (de) |
HU (2) | HUE035295T2 (de) |
IL (1) | IL211070A (de) |
LT (2) | LT2767537T (de) |
LU (1) | LUC00140I2 (de) |
MX (1) | MX2011001328A (de) |
NL (1) | NL301021I2 (de) |
NO (1) | NO2019042I1 (de) |
NZ (1) | NZ591166A (de) |
PL (2) | PL2767537T3 (de) |
PT (2) | PT2326650E (de) |
SG (2) | SG193842A1 (de) |
SI (2) | SI2326650T1 (de) |
TW (2) | TWI448464B (de) |
WO (1) | WO2010017055A2 (de) |
ZA (1) | ZA201100897B (de) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2466565T3 (es) | 2008-08-06 | 2014-06-10 | Biomarin Pharmaceutical Inc. | Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
US8841308B2 (en) | 2008-12-19 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Pyrazin-2-amines useful as inhibitors of ATR kinase |
US8541403B2 (en) * | 2010-02-03 | 2013-09-24 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
US20110190266A1 (en) * | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
RU2561732C2 (ru) * | 2010-02-08 | 2015-09-10 | Байомарин Фармасьютикал Инк. | Способы синтеза производных дигидропиридофталазинона |
WO2011130661A1 (en) * | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
EP2569313A1 (de) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Als art-kinasehemmer nützliche verbindungen |
AR083502A1 (es) * | 2010-10-21 | 2013-02-27 | Biomarin Pharm Inc | Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina |
WO2012166151A1 (en) * | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) |
WO2013028495A1 (en) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
SG11201401095YA (en) | 2011-09-30 | 2014-04-28 | Vertex Pharma | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
US9035053B2 (en) * | 2011-09-30 | 2015-05-19 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
MX353578B (es) | 2011-12-31 | 2018-01-19 | Beigene Ltd | Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp). |
JP5913631B2 (ja) * | 2011-12-31 | 2016-05-11 | ベイジーン リミテッド | Parp阻害剤としての縮合四環式または縮合五環式ピリドフタラジノン |
BR112014017833A2 (pt) | 2012-01-20 | 2021-03-23 | Dennis Brown | Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma |
LT2833973T (lt) | 2012-04-05 | 2018-02-12 | Vertex Pharmaceuticals Incorporated | Junginiai, tinkami naudoti kaip atr kinazės inhibitoriai, ir jų kombinuotas gydymas |
EP2904406B1 (de) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Verfahren zur bestimmung der durch atr-inhibition auftretenden vermehrten dna-schädigung |
WO2014073447A1 (ja) | 2012-11-08 | 2014-05-15 | 日本化薬株式会社 | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 |
RS59411B1 (sr) * | 2013-03-13 | 2019-11-29 | Forma Therapeutics Inc | Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodna jedinjenja kao inhibitori sintaze masnih kiselina (fasn) za lečenje kancera |
KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
WO2015069851A1 (en) | 2013-11-07 | 2015-05-14 | Biomarin Pharmaceutical Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
CN103772395B (zh) * | 2014-01-23 | 2016-05-11 | 中国药科大学 | 一类具有parp抑制活性的化合物、其制备方法及用途 |
CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
RS59054B1 (sr) | 2014-06-17 | 2019-08-30 | Vertex Pharma | Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora |
ES2947501T3 (es) * | 2014-07-31 | 2023-08-10 | Medivation Tech Llc | Sales coformadoras de (2S,3S)-metil 7-fluoro-2-(4-fluorofenil)-3-(1-metil-1h-1,2,4-triazol-5-il)-4-oxo-1,2,3,4-tetrahidroquinolin-5-carboxilato y procedimientos para prepararlas |
EP3265560B1 (de) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologe rekombinationsfaktoren |
EP3317277B1 (de) | 2015-07-01 | 2021-01-20 | Crinetics Pharmaceuticals, Inc. | Somatostatinmodulatoren und verwendungen davon |
CN107922425B (zh) | 2015-08-25 | 2021-06-01 | 百济神州有限公司 | 制备parp抑制剂、结晶形式的方法及其用途 |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
US9708319B1 (en) * | 2016-06-13 | 2017-07-18 | Yong Xu | Synthesis of PARP inhibitor talazoparib |
US11202782B2 (en) | 2016-09-27 | 2021-12-21 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors |
JP6541635B2 (ja) * | 2016-10-28 | 2019-07-10 | ベイジーン リミテッド | Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン |
CN108210461A (zh) * | 2016-12-16 | 2018-06-29 | 中国科学院上海药物研究所 | 一种Talazoparib药物组合物及其应用 |
CN107556312B (zh) * | 2016-12-29 | 2020-04-10 | 广州丹康医药生物有限公司 | 具有parp抑制活性的新型稠环化合物、其制备方法和用途 |
WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
CN107573341B (zh) * | 2016-12-29 | 2020-08-14 | 广州丹康医药生物有限公司 | 作为parp抑制剂的新型稠环化合物、其制备方法和应用 |
WO2018157794A1 (en) | 2017-02-28 | 2018-09-07 | Beigene, Ltd. | Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof |
CN110650961B (zh) * | 2017-05-08 | 2022-09-27 | 广州丹康医药生物有限公司 | Parp抑制剂、其药物组合物、制备方法和应用 |
EP3658560A4 (de) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | Somatostatinmodulatoren und verwendungen davon |
JP2020536887A (ja) | 2017-10-13 | 2020-12-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Parp阻害剤およびpd−1系結合アンタゴニストの組合せ |
TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
CN110272419A (zh) * | 2018-03-14 | 2019-09-24 | 上海艾力斯医药科技有限公司 | 二氢吡啶并酞嗪酮衍生物、其制备方法及应用 |
CN108341792B (zh) * | 2018-04-28 | 2021-09-17 | 苏州莱克施德药业有限公司 | 一种Volasertib中间体1-环丙基甲基哌嗪的制备方法 |
CN108676888B (zh) * | 2018-07-12 | 2022-01-28 | 吉林大学 | 一种肺部恶性肿瘤易感性预测试剂盒及系统 |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
WO2020092395A1 (en) | 2018-10-29 | 2020-05-07 | Forma Therapeutics, Inc. | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE |
WO2020095184A1 (en) | 2018-11-05 | 2020-05-14 | Pfizer Inc. | Combinations for treating cancer |
US20220227757A1 (en) | 2019-05-14 | 2022-07-21 | Suzhou Four Health Pharmaceuticals Co., Ltd. | Quinazoline-2,4-dione derivatives as parp inhibitors |
CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CN111116514B (zh) * | 2020-01-10 | 2024-03-19 | 广州科锐特生物科技有限公司 | 一种1-环丙甲酰基哌嗪盐酸盐的制备方法 |
WO2021181233A2 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
WO2022101828A1 (en) | 2020-11-13 | 2022-05-19 | Pfizer Inc. | Talazoparib soft gelatin capsule dosage form |
KR20230118597A (ko) | 2020-12-07 | 2023-08-11 | 화이자 인코포레이티드 | 탈라조파립을 사용한 치료에 감수성인 종양을 확인하는방법 및 그의 치료 방법 |
IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
MX2023011294A (es) | 2021-03-24 | 2023-10-05 | Pfizer | Combinacion de talazoparib y un antiandrogeno para el tratamiento del cancer de prostata sensible a la castracion metastasico mutado en el gen ddr. |
EP4319755A1 (de) * | 2021-04-08 | 2024-02-14 | Board of Regents, The University of Texas System | Verbindungen und verfahren für theranostisches targeting von parp-aktivität |
US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
EP4089093A1 (de) * | 2021-05-12 | 2022-11-16 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Radiosynthese von [18f]talazoparib |
WO2023131894A1 (en) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof |
WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
WO2023233295A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
WO2023239789A1 (en) * | 2022-06-08 | 2023-12-14 | Valo Health, Inc. | Tricyclic phthalazinone parp inhibitors and methods of use |
CN115572218B (zh) * | 2022-08-29 | 2024-04-16 | 江阴勒森生物科技有限公司 | 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法 |
WO2024074959A1 (en) | 2022-10-02 | 2024-04-11 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
WO2024127140A1 (en) | 2022-12-17 | 2024-06-20 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US106631A (en) * | 1870-08-23 | Improvement in seed-planter | ||
US4415504A (en) | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
JPS58225065A (ja) * | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | 2−キノロン誘導体 |
US5328905A (en) * | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
NZ291621A (en) | 1994-08-12 | 1998-09-24 | Myriad Genetics Inc | Isolation and detection of human breast cancer and ovarian cancer predisposing gene, brca1 |
ATE209660T1 (de) | 1994-08-12 | 2001-12-15 | Myriad Genetics Inc | 17q-verbundenes ovarial- und brustkrebs empfindlichkeitsgen |
GB9505538D0 (en) * | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
ID19155A (id) | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
DE19727410A1 (de) | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
TW430656B (en) | 1997-12-03 | 2001-04-21 | Dainippon Ink & Chemicals | Quinolinone derivative, method for preparing the same, and anti-allergic agent |
EP1077946A1 (de) | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Kondensierte trizkylische verbindungen, die parp hemmen |
DE19921567A1 (de) * | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
JP2001302669A (ja) * | 2000-04-18 | 2001-10-31 | Meiji Seika Kaisha Ltd | 三環性フタラジノン誘導体 |
JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
RU2292337C2 (ru) | 2002-02-19 | 2007-01-27 | Оно Фармасьютикал Ко., Лтд. | Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента |
EP1340819A1 (de) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mikrosatellitenmarker |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
EP1400244A1 (de) * | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | Neue spirokondensierte Chinazolinone und ihre Verwendung als Phosphodiesteraseinhibitoren |
AU2003277674A1 (en) * | 2002-11-12 | 2004-06-03 | Mochida Pharmaceutical Co., Ltd. | Novel parp inhibitors |
BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
JP4824566B2 (ja) * | 2003-05-28 | 2011-11-30 | エーザイ インコーポレーテッド | Parpを阻害するための化合物、方法、および医薬組成物 |
JP5084269B2 (ja) | 2004-02-18 | 2012-11-28 | アストラゼネカ アクチボラグ | テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用 |
GB0612971D0 (en) | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
AP2516A (en) | 2007-05-03 | 2012-11-26 | Pfizer Ltd | 2-Pyridine carboxamide derivatives as sodium channel modulators |
CA2697246A1 (en) | 2007-08-22 | 2009-02-26 | 4Sc Ag | Indolopyridines as inhibitors of the kinesin spindle protein (eg5) |
DK2209375T3 (da) * | 2007-10-03 | 2014-10-06 | Eisai Inc | Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf |
EP2247600A4 (de) | 2008-02-06 | 2011-09-14 | Biomarin Pharm Inc | Benzoxazolcarbonsäureamide als inhibitoren von poly(adp-ribose)polymerase (parp) |
ES2466565T3 (es) | 2008-08-06 | 2014-06-10 | Biomarin Pharmaceutical Inc. | Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
MX2011001563A (es) | 2008-08-12 | 2011-03-04 | Boehringer Ingelheim Int | Procedimiento para la preparacion de compuestos de piperazina sustituidos con cloalquilo. |
US8541403B2 (en) | 2010-02-03 | 2013-09-24 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
US20110190266A1 (en) * | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
RU2561732C2 (ru) | 2010-02-08 | 2015-09-10 | Байомарин Фармасьютикал Инк. | Способы синтеза производных дигидропиридофталазинона |
WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
WO2011140009A1 (en) | 2010-05-04 | 2011-11-10 | Biomarin Pharmaceutical Inc. | Methods of using semi-synthetic glycopeptides as antibacterial agents |
AR083502A1 (es) * | 2010-10-21 | 2013-02-27 | Biomarin Pharm Inc | Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina |
WO2012166151A1 (en) | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) |
WO2013028495A1 (en) | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
WO2015069851A1 (en) | 2013-11-07 | 2015-05-14 | Biomarin Pharmaceutical Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
ES2947501T3 (es) | 2014-07-31 | 2023-08-10 | Medivation Tech Llc | Sales coformadoras de (2S,3S)-metil 7-fluoro-2-(4-fluorofenil)-3-(1-metil-1h-1,2,4-triazol-5-il)-4-oxo-1,2,3,4-tetrahidroquinolin-5-carboxilato y procedimientos para prepararlas |
-
2009
- 2009-07-27 ES ES09805360.6T patent/ES2466565T3/es active Active
- 2009-07-27 PL PL14154664T patent/PL2767537T3/pl unknown
- 2009-07-27 CN CN200980139634.2A patent/CN102171214B/zh active Active
- 2009-07-27 EP EP14154664.8A patent/EP2767537B1/de active Active
- 2009-07-27 SG SG2013065719A patent/SG193842A1/en unknown
- 2009-07-27 CA CA2732797A patent/CA2732797C/en active Active
- 2009-07-27 DK DK09805360.6T patent/DK2326650T3/en active
- 2009-07-27 KR KR1020117005152A patent/KR101846029B1/ko active IP Right Grant
- 2009-07-27 CN CN201410003342.9A patent/CN103896942A/zh active Pending
- 2009-07-27 LT LTEP14154664.8T patent/LT2767537T/lt unknown
- 2009-07-27 PT PT98053606T patent/PT2326650E/pt unknown
- 2009-07-27 AU AU2009279944A patent/AU2009279944B2/en active Active
- 2009-07-27 HU HUE14154664A patent/HUE035295T2/en unknown
- 2009-07-27 EP EP09805360.6A patent/EP2326650B9/de active Active
- 2009-07-27 PT PT141546648T patent/PT2767537T/pt unknown
- 2009-07-27 BR BRPI0917119-3A patent/BRPI0917119B1/pt active IP Right Grant
- 2009-07-27 WO PCT/US2009/051879 patent/WO2010017055A2/en active Application Filing
- 2009-07-27 SG SG10201809895YA patent/SG10201809895YA/en unknown
- 2009-07-27 SI SI200930881T patent/SI2326650T1/sl unknown
- 2009-07-27 US US12/510,096 patent/US8012976B2/en active Active
- 2009-07-27 DK DK14154664.8T patent/DK2767537T3/da active
- 2009-07-27 EP EP17161893.7A patent/EP3241832A1/de not_active Withdrawn
- 2009-07-27 MX MX2011001328A patent/MX2011001328A/es active IP Right Grant
- 2009-07-27 NZ NZ591166A patent/NZ591166A/xx unknown
- 2009-07-27 CN CN201410640197.5A patent/CN104478875B/zh active Active
- 2009-07-27 ES ES14154664.8T patent/ES2625817T3/es active Active
- 2009-07-27 SI SI200931668T patent/SI2767537T1/sl unknown
- 2009-07-27 PL PL09805360T patent/PL2326650T3/pl unknown
- 2009-07-27 JP JP2011522113A patent/JP5984389B2/ja active Active
- 2009-08-04 GB GB0913474A patent/GB2462361A/en not_active Withdrawn
- 2009-08-05 TW TW098126400A patent/TWI448464B/zh active
- 2009-08-05 AR ARP090102999A patent/AR072970A1/es active IP Right Grant
- 2009-08-05 TW TW103106940A patent/TW201422617A/zh unknown
-
2011
- 2011-02-03 IL IL211070A patent/IL211070A/en active Protection Beyond IP Right Term
- 2011-02-03 ZA ZA2011/00897A patent/ZA201100897B/en unknown
- 2011-03-31 US US13/077,785 patent/US8420650B2/en active Active
- 2011-11-04 HK HK11111926.3A patent/HK1157755A1/xx unknown
-
2013
- 2013-03-06 US US13/787,496 patent/US8999987B2/en active Active
-
2014
- 2014-03-28 CY CY20141100240T patent/CY1115022T1/el unknown
-
2015
- 2015-02-03 HK HK15101138.4A patent/HK1200813A1/xx unknown
- 2015-02-26 US US14/632,825 patent/US9820985B2/en active Active
- 2015-04-30 JP JP2015093417A patent/JP2015157843A/ja active Pending
-
2017
- 2017-05-31 CY CY20171100578T patent/CY1119218T1/el unknown
- 2017-06-29 HR HRP20170982TT patent/HRP20170982T1/hr unknown
- 2017-07-27 JP JP2017145036A patent/JP2018012698A/ja active Pending
- 2017-09-28 US US15/719,534 patent/US10543209B2/en active Active
-
2019
- 2019-11-28 NO NO2019042C patent/NO2019042I1/no unknown
- 2019-11-28 CY CY2019044C patent/CY2019044I2/el unknown
- 2019-12-03 FR FR19C1071C patent/FR19C1071I2/fr active Active
- 2019-12-05 LT LTPA2019522C patent/LTC2767537I2/lt unknown
- 2019-12-11 LU LU00140C patent/LUC00140I2/fr unknown
- 2019-12-11 NL NL301021C patent/NL301021I2/nl unknown
- 2019-12-13 US US16/714,474 patent/US10780088B2/en active Active
- 2019-12-19 HU HUS1900053C patent/HUS1900053I1/hu unknown
-
2020
- 2020-08-21 US US17/000,271 patent/US11364241B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR19C1071I2 (fr) | Inhibiteurs de type dihydropyridophthalazinone de poly(adp-ribose)polymerase (parp) | |
HUS1800022I1 (hu) | Amid-szubsztituált indazol-származékok mint poli(ADP-ribóz)-polimeráz (PARP) inhibitorok | |
BRPI1007358A2 (pt) | inibidores de poli (adp-ribose) polimerase (parp) | |
BRPI0820236A2 (pt) | Derivados de piridazinona como inibidores parp | |
BRPI0921327A2 (pt) | Combinação de herbicida-protetor | |
BRPI0919818A2 (pt) | inibidores de seprase seletivos | |
BRPI0917808A2 (pt) | inibidores de cmet | |
BRPI0922158A2 (pt) | nanoemulsões | |
BRPI0908115A2 (pt) | torneira | |
BRPI0812825A2 (pt) | Derivados ftalazinona como inibidores de parp-1 | |
BRPI0923497A2 (pt) | derivados de piridazinona | |
BRPI0811044A2 (pt) | 2-morfolin-4-il-pirimidinas como inibidores de p13k. | |
BRPI0812387A2 (pt) | Macadores de polinucleotídeo | |
DK2280962T5 (da) | Pyridazinonderivater | |
ATE527260T1 (de) | (dihydro)pyrroloä2,1-aüisoquinoline | |
BRPI0917673A2 (pt) | Combinação de herbicida-protetor compreendendo difluorometanossulfonilanilidas substituidas por dimetoxitriazinila | |
BRPI0716198A2 (pt) | Pirrolo-isoquinolinas como inibidores de cinase | |
BRPI0922728A2 (pt) | combinação de herbicida-antídoto | |
BRPI0822141A2 (pt) | Microfibra | |
BRPI0911967A2 (pt) | quinazolinas substituídas | |
BRPI0910234A2 (pt) | terpolímeros de 1-buteno | |
SE0702098L (sv) | Hållaranordning | |
ITSV20080002A1 (it) | Paraurti shift | |
ITVA20070044U1 (it) | Abbracciatovagliolo - abbraccia tovagliolo | |
ES1069154Y (es) | Mecanismo escurridor de fregona |